Semax Dosage: What the Evidence Says (2026)
Not FDA-approved
Nasal ACTH-fragment peptide used in Russia. Not FDA-approved; no FDA-reviewed dosing.
Also called: ACTH(4-10) analogue
Regulatory status (US)
Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names it for use in the nose only.
What it is
A seven-amino-acid peptide built on a fragment of ACTH, a pituitary hormone, given as nasal drops.
Dosage
What human studies show
- Clinical studies are almost all Russian-language. There is no FDA-reviewed dosing.
Safety
- FDA concerns include immune reactions and limited safety data.
Questions
- Is Semax FDA-approved?
- Not approved by the FDA for any use. FDA removed it from its "significant safety risk" compounding list in April 2026 after the nomination was withdrawn, and an FDA advisory committee voted in favor of allowing pharmacy compounding in July 2026, against the recommendation of FDA staff. On October 30, 2026, HHS published a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies that compound it for a named patient with a prescription, under listed conditions and routes. That is not an FDA approval and says nothing about safety or effectiveness. The draft policy names it for use in the nose only.
- What dose of Semax has been studied?
- There is no established human dose. Clinical studies are almost all Russian-language. There is no FDA-reviewed dosing.
Related
The first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.
BPC-15715-amino-acid peptide studied mostly in animals. Not approved; no established human dose.
TB-500 (thymosin beta-4)Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.
GHK-Cu (copper peptide)Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.
Sources
- FDA: Certain bulk drug substances for compounding that may present significant safety risks
- Federal Register (public inspection) 2026-07361: peptide category changes
- Manufacturing Chemist: FDA panel backs six peptides for pharmacy compounding
- Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
Last checked 2026-11-16. How we pick and check sources: methodology.